1-4 of 4
Hans Klingemann, MD PhD
Close
Sort by
Journal Articles

Providing a Homing Receptor for CAR Engineered NK Cells - Improving Cellular Immunotherapy for B-Cell Lymphoma

Nathan Thomas Schomer, BS, MS, Laurent Boissel, PhD, Karen Jiang, PhD, Hans Klingemann, MD PhD, John H. Lee, MD F.A.C.S, Patrick Soon-Shiong, MD FRCS(C), FACS
Journal: Blood
Blood (2018) 132 (Supplement 1): 4547.
https://doi.org/10.1182/blood-2018-99-116890
Published: 2018
Journal Articles

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Michael Boyiadzis, MD MHSc, Mounzer Agha, MD, Robert L Redner, MD, Alison Sehgal, MD, Annie Im, MD, Jing-Zhou Hou, Rafic Farah, MD, Kathleen A. Dorritie, MD, Anastasios Raptis, MD PhD, Seah H. Lim, MDPhDFRCP,FRCPath,MBBS, Hans Klingemann, MD PhD, Hong Wang, PhD, Natalia Lapteva, PhD, Mei Zhuyong, MD, Lisa H Butterfield, PhD, Cliona M. Rooney, PhD, Theresa L Whiteside, PhD
Journal: Blood
Blood (2016) 128 (22): 1649.
https://doi.org/10.1182/blood.V128.22.1649.1649
Published: 2016
Journal Articles

Intra-Tumor Injection of CAR-Engineered NK Cells Induces Tumor Regression and Protection Against Tumor Re-Challenge

Laurent Boissel, PhD, Hans Klingemann, MD PhD, Junaid Khan, PhD, Patrick Soon-Shiong, MD FRCS (C), FACS
Journal: Blood
Blood (2016) 128 (22): 466.
https://doi.org/10.1182/blood.V128.22.466.466
Published: 2016
Journal Articles

Mitoxantrone and Melphalan Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia.

Kellie Sprague, MD, Vaishalee Padgaonkar, MD, Andreas K. Klein, MD, Geoffrey W. Chan, MD, Kenneth B. Miller, MD, Hans Klingemann, MD/PhD
Journal: Blood
Blood (2005) 106 (11): 5512.
https://doi.org/10.1182/blood.V106.11.5512.5512
Published: 2005